Details of the Drug

General Information of Drug (ID: DMSPN58)

Drug Name
Clomethiazole
Synonyms
Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV
Indication
Disease Entry ICD 11 Status REF
Stroke 8B20 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 161.65
Logarithm of the Partition Coefficient (xlogp) 2.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 33 mL/min/kg [3]
Elimination
0.05% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.5 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.9352 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.36% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.6 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [2]
Chemical Identifiers
Formula
C6H8ClNS
IUPAC Name
5-(2-chloroethyl)-4-methyl-1,3-thiazole
Canonical SMILES
CC1=C(SC=N1)CCCl
InChI
InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3
InChIKey
PCLITLDOTJTVDJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10783
ChEBI ID
CHEBI:92875
CAS Number
533-45-9
DrugBank ID
DB06470
TTD ID
D0G3LM
INTEDE ID
DR0348

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor gamma-3 (GABRG3) TTEX6LM GBRG3_HUMAN Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [6]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [6]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02374567) Pharmacovigilance in Gerontopsychiatric Patients. U.S. National Institutes of Health.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62.
6 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
7 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.